NCT00088491已完成3 期
A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,205
- 试验地点
- 5
- 主要终点
- Determine comparative efficacy in patients with schizophrenia of non-inferiority of IM olanzapine depot high and low doses versus oral olanzapine based on exacerbation rates after 6 months of maintenance treatment
研究概览
简要总结
This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine; evaluate different doses of IM olanzapine depot; and determine the blood levels of IM olanzapine depot in patients at different points in time after an injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have schizophrenia
- •Patients must be clinically stable on antipsychotic medication
- •Patients must be retrospectively judged by investigators, based on clinical interview and impression, to have been stable (with respect to their symptoms of schizophrenia) for at least 4 weeks entry into the study
- •Patients must be an outpatient and have BPRS positive items scores of 4 or less to enter the study
- •Female patients of childbearing potential must be using a medically accepted means of contraception.
排除标准
- •Patients must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry.
- •Female patients must not be pregnant or breast-feeding
- •Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia
- •Patients must not require concomitant treatment with any other medication with primarily central nervous system activity, including antidepressants, mood stabilizers, and anticonvulsants.
- •Patients must not have a substance (except nicotine or caffeine) dependence within the past 30 days
结局指标
主要结局
Determine comparative efficacy in patients with schizophrenia of non-inferiority of IM olanzapine depot high and low doses versus oral olanzapine based on exacerbation rates after 6 months of maintenance treatment
Determine comparative efficacy in patients with schizophrenia of superiority of IM olanzapine depot low, med and high doses versus very low dose based on time to exacerbation of symptoms of schizophrenia
次要结局
- Demonstrate non-inferior efficacy in terms of exacerbation rates of high plus low dose IM olanzapine depot versus medium dose
- Provide information on transition of patients stabilized on oral olanzapine 10, 15 or 20 mg/day to therapeutic doses of IM olanzapine depot
- Demonstrate superiority of high dose, medium dose and low dose IM olanzapine depot compared with very low dose IM olanzapine depot in change from baseline to endpoint in PANSS total, positive, negative and general subscales
- Assess the safety and tolerability of high plus low dose IM olanzapine depot versus oral olanzapine
- Assess the safety and tolerability of medium dose IM olanzapine depot versus oral olanzapine
- Assess the safety and tolerability of each IM olanzapine depot treatment group versus very low dose IM olanzapine depot
- Compare the efficacy of high plus low dose IM olanzapine depot versus oral olanzapine during maintenance treatment on quality of life, drug attitude inventory, resource utilization and hospitalization measures
- Compare the efficacy of high, medium and low doses of IM olanzapine depot during maintenance treatment on quality of life, drug attitude inventory, resource utilization and hospitalization measures
- Characterize the pharmacokinetics of olanzapine following multiple dosing with IM olanzapine depot at each of the prescribed dosing regimens and to compare IM olanzapine depot pharmacokinetics with oral olanzapine pharmacokinetics
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With SchizophreniaSchizophreniaNCT00088478Eli Lilly and Company402
已完成
3 期
Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With SchizophreniaSchizophreniaNCT00485901Eli Lilly and Company50
已完成
3 期
Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in SchizophreniaAgitationSchizophreniaSchizoaffective DisorderNCT00797277National Taiwan University Hospital67
已完成
4 期
Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific PancreatitisPancreatitis, ChronicNCT00956839Sanjay Gandhi Postgraduate Institute of Medical Sciences40
尚未招募
3 期
A Study of Olanzapine in Patients With Acute AgitationAcute AgitationNCT05803642Qilu Pharmaceutical Co., Ltd.318